Transcriptomics

Dataset Information

0

Eribulin induces mesenchymal-epithelial transition to curtail metastatic progression by altering the chromatin landscape of breast cancers cells [scRNA-Seq]


ABSTRACT: The epithelial-mesenchymal transition (EMT) is a developmental program that is co-opted by tumor cells to aid in their embarking on the metastatic cascade. Tumor cells that undergo EMT are known to be endowed by, amongst other traits, heightened resistance to chemotherapy. Despite a clear understanding of the role played by the EMT program in conferring cells with these aggressive traits, there are currently no therapeutic avenues specifically targeting the program. Here we show that treatment of mesenchymal-like breast cancer cells with eribulin, an FDA-approved drug for the treatment of advanced breast cancers, leads to a mesenchymal-epithelial transition (MET), accompanied by a loss of metastatic propensity and sensitization of tumor cells to subsequent rounds of chemotherapy. We uncover a novel alternate mechanism of action that provides evidence for eribulin pretreatment as a viable clinical mechanism of MET induction that curtails metastatic progression and the evolution of therapy resistance.

ORGANISM(S): Mus musculus

PROVIDER: GSE207690 | GEO | 2023/08/02

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-08-02 | GSE207595 | GEO
2023-08-02 | GSE207772 | GEO
2023-08-02 | GSE207771 | GEO
2023-08-02 | GSE207769 | GEO
2023-08-02 | GSE207767 | GEO
2019-11-13 | PXD012942 | Pride
2012-07-23 | E-GEOD-24868 | biostudies-arrayexpress
2023-12-13 | MODEL2208050002 | BioModels
2012-07-24 | GSE24868 | GEO
2023-12-13 | MODEL2208050001 | BioModels